Objective-To evaluate whether prophylactic treatment with metoprolol for two years after coronary artery bypass grafting improves working capacity and reduces the occurrence of myocardial ischaemia in patients with coronary artery disease. (Br Heart3 1995;74:235-241) 
two years. Two years after randomisation, a computerised 12-lead electrocardiogram was obtained during a standardised bicycle exercise test in 618 patients (64% of all those randomised). Results-The median exercise capacity was 140 W in the metoprolol group (n = 307) and 130 W in the placebo group (n = 311) (P > 0. 20 ). An ST depression of > 1 mm at maximum exercise was present in 34% of the patients in the metoprolol group and 38% in the placebo group (P > 0. 20) and an ST depression of >2 mm at maximum exercise was present in 11% in the metoprolol group and 16% in the placebo group (P = 0.09). The median values for maximum systolic blood pressure were 200 mm Hg in the metoprolol group and 210 mm Hg in the placebo group (P < 0.0001), while the median values for maximum heart rate were 126 beatsimin in the metoprolol group and 143 beats/min in the placebo group (P < 0.0001). Coronary artery bypass grafting (CABG) is a frequent and costly procedure in coronary artery disease, and is performed with the primary objective of relieving pain and improving survival.' 2 The underlying atherosclerotic disease remains,3 and the recurrence of symptoms is common after several years. 4 The return of angina pectoris in the increasing population of patients who have undergone CABG calls for medication for angina and possibly subsequent revascularisation. It is therefore important to find a means of decreasing the reappearance of angina pectoris. Animal studies have indicated that atherosclerosis decreases during treatment with metoprolol,5 a selective f, adrenoceptor blocking agent. In a consecutive series of patients who underwent CABG, we performed a double blind randomised study to evaluate the effect of metoprolol on the development of ischaemic events, exercise capacity, and signs of myocardial ischaemia two years after CABG. Working capacity and signs of exercise induced ischaemia were evaluated in a bicycle exercise test two years after CABG in the metoprolol and placebo groups. The occurrence of ischaemic events in the exercised patients was studied. The aim of the present study was to evaluate whether treatment with metoprolol for two years after CABG improves exercise capacity and reduces signs of myocardial ischaemia.
Methods

PATIENTS
All the patients from western Sweden who underwent CABG at Sahlgrenska University Hospital and the Scandinavian Heart Centre, Goteborg, between June 1988 and June 1991 were evaluated for inclusion in a double blind randomised study of the anti-ischaemic effects of metoprolol after bypass surgery during two years of treatment. Between four and 21 days after CABG, patients were randomised to receive 100 mg of metoprolol every day for two weeks and thereafter 200 mg of metoprolol every day for two years, or placebo. Patients were recruited from all 15 hospitals in the south western region of Sweden. During the study period, 2365 patients underwent CABG, of whom 967 (41%) were included in the metoprolol study. The exclusion criteria were simultaneous valve surgery (n = 261, 19%), unwillingness or inability to give informed consent (n = 254, 18%), need for open treatment withf3 blockade (n = 194, 14%), age > 75 years (n = 170, 12%), systolic blood pressure < 100 mm Hg (n = 57, 4%), severe obstructive pulmonary disease (n = 62, 4%), participation in other randomised trials (n = 61, 4%), and death (n = 42, 3%). Eighty seven patients (6%) were excluded due to a heart rate of < 45 beats/min, severe heart failure, poor peripheral circulation, advanced atrioventricular block, or previous participation in the study. Three hundred and eighty seven patients (28%) were excluded for other reasons. Among these, 74 patients (8% of all) were never evaluated for inclusion before their death. Frequent conditions registered as other reasons included: the patient reported intolerance to fi blockade, though not confirmed or assessed as a contraindication by the treating physician; the patient was unwilling to discontinue medication with metoprolol after CABG; and reported hypertension where ,B blockade was approved by the patient and the physician. More than one reason for exclusion may have been recorded for each patient. Two years after CABG, the trial protocol specified that all randomised patients were summoned for exercise testing at the referring hospital. A two year exercise test was performed by 618 (64%) of the study participants. The end of the electrocardiographic PR segment was used as the reference point for ST measurements and the ST amplitude 60 ms after the J point was used as the ST level. ST amplitude changes were recorded in leads aVF, V2, and V5 in the study protocol.910 The exercise test protocol specified an assessment of myocardial ischaemia based on the ECG reaction: a horizontal or downsloping ST segment depression of 1 mm or more was regarded as a positive ECG reaction for myocardial ischaemia if it occurred during maximum exercise or within four minutes after exercise.
The test protocol also specified a physician's comprehensive assessment of the exercise test, which was performed by one of the investigators (HS) blinded to the clinical history. The physician's assessment was made according to the following classification. Definite myocardial ischaemia: The ECG showed changes consistent with the definition of exercise induced myocardial ischaemia at maximum exercise or four minutes after. The resting ECG was normal, or without confounding abnormalities such as bundle branch block, ST segment depression at rest, Q wave, or QS complex. Probable myocardial ischaemia:
The clinical appearance was consistent with exercise induced myocardial ischaemia but the ECG criteria were questionable. For example: the patient revealed chest pain consistent with angina pectoris in the presence of bundle branch block, pacemaker ECG, Q wave, QS complex, or considerable ST depression in the resting ECG. Indeterminate: The exercise ECG did not reveal enough information either to confirm or rule out myocardial ischaemia. No ischaemia: The test revealed no chest pain or ECG changes consistent with myocardial ischaemia. Tests were also regarded as positive by the physician in cases in which the significant ST segment depression occurred in a lead that was not recorded in the study protocol, since the physician's assessment was based on ST amplitude changes in all recorded leads, and the complete exercise ECG was available for the investigator at the time of assessment. ST segment measurements were only used in the statistical analysis when measurements were recorded in all three leads in the protocol. For example, when evaluating ST segment depression > 1 mm, we required that readings were submitted to us from all three leads (aVF, V2, and V5). The number of observations noted in the tables differs due to incomplete data in the study protocols. Most analogous ECGs registered only precordial leads during exercise, and were thus not included in this analysis.
STATISTICAL ANALYSIS
Fisher's permutation test, including Fisher's exact test for dichotomous variables, was used to test for differences between groups. In the tables, P values are only given when they are below 0-05. All P values are two tailed and, in line with practice, no corrections for multiple comparisons have been made. Therefore, P values of borderline significance (P < 0 05) should be regarded with caution.
Results
Of all the patients who underwent CABG during the study period, 967 participated in the metoprolol trial. Of these, 618 performed an exercise test two years after CABG and are included in the present analysis. This constituted 64% of the patients in the metoprolol trial and 26% of all the patients operated on during the study period. One hundred and ten patients in the placebo group and 83 patients in the metoprolol group had been withdrawn from blind medication before the time of the postoperative exercise ECG.
BASELINE CHARACTERISTICS (tables 1 and 2)
The metoprolol and placebo groups were comparable in terms of clinical characteristics at operation. More patients in the metoprolol group were under 65 years of age, but the difference in age was not significant for the overall age distribution. Patients who did not perform the two year exercise test follow up suffered from more severe heart disease than those who participated. They had a higher prevalence of congestive heart failure, diuretic treatment, hypertension, and more advanced anginal class, and they were older than the patients who took part in the exercise tests.
The median values for maximum exercise capacity were 140 W in the metoprolol group and 130 W in the placebo group. Among males, the median values for maximum exercise capacity were 140 W in both groups and the corresponding figures among females were 90 W in both groups.
BLOOD PRESSURE AND HEART RATE (table 3) There was a significantly lower median systolic blood pressure and heart rate in the metoprolol group at 70 W, at maximum exercise, and four minutes after exercise as compared to placebo. The resting diastolic blood pressure and heart rate were also found to be lower in the metoprolol group. The numbers of observations differ because of incomplete data in the study protocols. Work load (W) Figure 1 Exercise capacity two years after coronary artery bypass grafting in metoprolol (n = 306) and placebo (n = 311) groups minutes after, in a greater proportion of the placebo patients compared to the metoprolol group, although the difference was not significant. Definite or probable myocardial ischaemia, by the investigator's assessment, was adjudged to be present in 33% of patients in the placebo group and 27% in the metoprolol group (P = 0-11). There was no significant difference between the metoprolol and placebo groups with respect to the proportion with angina pectoris during exercise, 16% versus 11% (P = 007). The mean chest pain score was significantly higher in the metoprolol group than in the placebo group (P = 0-001).
When the groups were analysed in terms of actual treatment, we found a lower exercise capacity in the group treated with any kind of/B blockade (P = 0-02), but no significant difference in the incidence and severity of ST depression during exercise.
IMPROVEMENT IN EXERCISE PERFORMANCE (fig 2)
There was no difference between the groups with respect to improvement in exercise capacity. The median improvement in exercise capacity was 30 W in both treatment groups. The results were similar among patients still on blind medication at the time of exercise and among patients who had stopped blind treatment prematurely.
FURTHER OBSERVATIONS (table 6) The prevalence and distribution of reasons for terminating exercise did not differ between the groups. Half the patients in both treatment groups therefore stopped the exercise because of general tiredness. This was followed, in order of frequency, by leg tiredness, dyspnoea, and chest pain, which occurred with a similar frequency in the two groups. The proportion of patients with any ventricular premature beats during exercise was considerable in both treatment groups, although it was significantly more common in the placebo group (P = 0 005), just exceeding half of all exercised patients, as compared with 41% in the metoprolol group. The occurrence of higher numbers of ventricular premature beats (> 5/min) was also more common in the placebo group, although the significance was weaker (P = 0-04). Withdrawal from treatment was more common in the placebo group than in the metoprolol group, at 35% versus 27% (P = 0 03). Open ,B blockade treatment was also significantly more common in the placebo group (P = 0 004), as was treatment with digitalis (P = 0 006).
CLINICAL EVENTS AND REASONS FOR WITHDRAWAL (table 7)
There was no significant difference in the clinical event rate between the two treatment blockade: 19% versus 7% in the metoprolol group (P < 0.0001). Bradycardia was more often a reason for withdrawal in the metoprolol group (P = 0 04).
Discussion
This study describes exercise capacity and signs of myocardial ischaemia at exercise two years after CABG in a double blind randomised study of metoprolol. No significant difference in working capacity, functional improvement, ST segment depression, or the presence of angina was found between the groups.
LIMITATIONS
Patient selection
The patients participating in the present analysis represent 26% of the patients who underwent CABG during the study period.
Patients in need of ft blockade for clinical reasons and patients with an intolerance to ft blockade were excluded from participation in the main study. The participants therefore represent a selected group of patients. Whether the findings in this study can be extrapolated to an unselected group of patients can be questioned. Furthermore, only two thirds of the patients participating in the metoprolol trial performed a two year exercise test. The reasons for omission were not recorded, although in 42% it was attributed to lack of systematic follow up at two centres. The baseline data for non-participants show more advanced heart disease in this group, thereby representing a selection towards healthier patients performing exercise tests. The omission of the more severely diseased patients decreases the sensitivity of the study. However, this kind of selection is likely to be present in all exercise test studies.
In this analysis, 31% of the patients were withdrawn from blind treatiment prematurely.
More patients in the placebo group withdrew prematurely compared with the metoprolol group, thereby creating difficulties in the interpretation of the data. This was largely explained by open treatment with f blockade in the placebo group: 21% compared with 12% in the metoprolol group (P = 0004). We therefore expect the patients in greatest need of therapy with metoprolol to have received this openly, thereby reducing the possibility of detecting any differences between groups.
Electrocardiographic technique and study design Several ECG recording systems were used, making the interpretation of the data more complex. The decision to record only leads aVF, V2, and V5 may have decreased the sensitivity of the method. ST segment depression after myocardial infarction has been shown to be less frequent after treatment with metoprolol at submaximum exercise.22 However, in a patient group with suspected myocardial infarction, ST depression occurred at a similar frequency among patients treated with metoprolol, as compared to placebo, at exercise. 2' There was a trend towards better performance in the metoprolol group, but the difference was not significant. There was also a trend, by ST depression criteria and by physician's assessment, indicating less myocardial ischaemia among patients randomised to metoprolol. The clinical data suggest that the patients who refrained from exercise testing were at higher risk, and this may have been a group which would have benefitted from /3 blockade. It is possible that if all of the potential study group had been exercised such a change would have been confirmed. However, any speculations about a beneficial effect of,B blockade were offset by the observations of a trend towards higher prevalence of chest pain adjudged as angina (NS), and a higher mean chest pain score in the metoprolol group (P = 0001).
As in other studies, the presence of ST segment changes-assessed as silent myocardial ischaemia-after CABG was considerable ( probable myocardial ischaemia than the number of patients who fulfilled the ECG criteria for myocardial ischaemia. This difference was partly explained by the fact that the ECG criteria rigorously specified ST depression of > 1 mm, and did not account for the presence of, for example, signs of left ventricular hypertrophy, bundle branch block, other ST depression at rest, Q waves, QS complexes, or pacemaker rhythm in the resting ECG. The value of ST segment depression during exercise in the diagnosis of myocardial ischaemia after CABG has been questioned.2526 However, the prognosis has been shown to correlate with ST segment depression and functional improvement. 24 The best exercise performance and the least ST segment depression have been observed in patients with the most complete revascularisation.2728
When the exercise tests were analysed in relation to the actual treatment with ,B blockade, we found a difference in favour of no treatment. One reason for this may be that among patients withdrawn from blind medication and treated with open ,B blockade, a large proportion actually had myocardial ischaemia. They were expected to have a poorer exercise performance. Another explanation may be that asymptomatic participants randomised to metoprolol treatment two years after CABG are very similar to patients without coronary artery disease and are thus expected to perform less well on /3 blockade treatment.
In summary, patients who have undergone CABG constitute a complex group in terms of the degree of revascularisation to the myocardium, left ventricular function, and the presence of ischaemic symptoms, which may in part explain the lack of difference between the treatment groups in terms of exercise capacity and occurrence of ST segment depression.
OTHER FINDINGS
Systolic blood pressure and heart rate at exercise were higher in the placebo group, thereby corresponding with previous studies on the effect of /3 blockade in stable angina 516 and after myocardial infarction. 29 The higher prevalence of ventricular premature beats in the placebo group was in agreement with previous experience of patients treated with 3 blockade after myocardial infarction. 14 30 However, ventricular ectopy after CABG has not been found to be related to prognosis,'2"3 thus indicating that this effect is of lesser importance. A considerable proportion of patients in both treatment groups had ventricular premature beats during exercise, just above half in the placebo group versus 41% in the metoprolol group (P = 0005). We therefore chose to present data for more than five ventricular premature beats per minute, in order to evaluate if the group differences remained or increased. Occurrence of several ventricular premature beats was also less frequent in the metoprolol group, although the difference was only of borderline significance (P = 004; 
